Dhanwantari Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 16 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2.27%
(FY 2020)
- Profit 3.22%
(FY 2020)
- Ebitda 124.32%
(FY 2020)
- Net Worth 12.17%
(FY 2020)
- Total Assets 1.42%
(FY 2020)
About Dhanwantari Therapeutics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kamalakara Pantangi and Jayasree Pantangi serve as directors at the Company.
- CIN/LLPIN
U24100TG2008PTC058165
- Company No.
058165
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Mar 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dhanwantari Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamalakara Pantangi  | Director | 14-Mar-2008 | Current |
| Jayasree Pantangi | Director | 14-Mar-2008 | Current |
Financial Performance of Dhanwantari Therapeutics.
Dhanwantari Therapeutics Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.27% increase. The company also saw a slight improvement in profitability, with a 3.22% increase in profit. The company's net worth Soared by an impressive increase of 12.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dhanwantari Therapeutics?
In 2017, Dhanwantari Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sree Raghavendra Hospitals Pvt LtdActive 30 years 5 monthsKamalakara Pantangi and Jayasree Pantangi are mutual person
Dfi Publications Private LimitedActive 16 years 8 monthsKamalakara Pantangi and Jayasree Pantangi are mutual person
- Sree Siva Raghavendra Remedies Private LimitedActive 23 years 7 months
Kamalakara Pantangi is a mutual person
- Dfi Nirmaan Private LimitedActive 14 years 11 months
Kamalakara Pantangi and Jayasree Pantangi are mutual person
- Dfi Ventures LimitedActive 14 years 11 months
Kamalakara Pantangi and Jayasree Pantangi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dhanwantari Therapeutics?
Unlock and access historical data on people associated with Dhanwantari Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dhanwantari Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dhanwantari Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
